Last reviewed · How we verify

NCT05411874

A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP

Status unknown Phase 2 Last updated 9 June 2022
What this trial tests

Phase 2 trial testing Chidamide in Thrombocytopenia in 100 participants. Status unknown.

Timeline
1 October 2022
Primary endpoint
30 October 2023
30 October 2024

Quick facts

Lead sponsorShandong University
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 October 2022
Primary completion30 October 2023
Estimated completion30 October 2024

Drugs / interventions tested

Conditions studied

Sponsor

Shandong University

Who can join

Adults 18 to 70, any sex, with Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recently, histone deacetylase inhibitors (HDACi) has been used for their anti-inflammatory and immunomodulatory activities. It has been shown that HDACi can alleviate graft-versus-host disease by enhancing the number and function of Foxp3+ Tregs. Our group found that low-dose HDACi alleviated thrombocytopenia in both passive and active murine models of ITP. Furthermore, low-dose HDACi attenuated macrophage phagocytosis of antibody-coated platelets, stimulated production of natural Foxp3+ Tregs, promoted peripheral conversion of T cells into Tregs, and restored Treg suppressive function in vivo and in vitro. The project was undertaking by Qilu Hospital of Shandong University and other 10 well-known hospitals in China. In order to report the efficacy and safety of the low dose chidamide combined with high-dose dexamethasone versus high-dose dexamethasone in the management of ITP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Chidamide

Trials testing the same drug.

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

Other Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing